U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527936) titled 'A Study of BEN301 Injection in theTreatment of Autoimmune Diseases' on April 07.
Brief Summary: The study aims to investigate the safety, tolerability, and preliminary clinical efficacy of BEN301 Injection in patients with autoimmune diseases. In patients with autoimmune diseases, Treg cells are typically deficient or dysfunctional. CAR-Treg cell therapy represents a promising strategy for the treatment of autoimmune diseases and may be applicable to a broad spectrum of autoimmune conditions. Preclinical studies have shown that BEN301 Injection not only effectively suppresses the aberrant activation of T and B cells in SLE models, ...